Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show

Reviewed 16 sourcesPublished by PepVault

Zenagamtide is amycretin's official name: Novo's one-molecule GLP-1 and amylin drug. The trial results, all 36 registry trials and when phase 3 data is due.

A hand in a blue sleeve holds a white mug at a sunny table with berries, an apple and a glass of water
Last reviewed
Sources
16
Questions
8
Compounds
5

The short answer

Zenagamtide is amycretin's official name, recommended by the WHO in 2026 for Novo Nordisk's single molecule that switches on both the GLP-1 and the amylin receptors. It is not approved anywhere. In trials, weekly shots took off 22% to 24% of body weight over 36 weeks in obesity and up to 14.6% in type 2 diabetes. Phase 3 began in February 2026.

  • Zenagamtide, amycretin and NNC0487-0111 are one drug: the WHO name, the development name and Novo's code.
  • One chain carries a GLP-1 piece and an amylin piece, the two signals CagriSema gives as two drugs.
  • Weekly shots: 24.3% weight loss at 36 weeks on 60 mg in a 125-person trial; up to 14.6% in type 2 diabetes.
  • 19 phase 3 trials are listed, shot and tablet; the earliest primary completions fall in mid-2028.

Every number checked at its primary source · · 16 sources · How we research

Evidence: Early human evidence: two phase 1 trials, a 125-person phase 1b/2a trial and two 36-week phase 2 trials in type 2 diabetes, all randomized and all funded by Novo Nordisk. Nineteen phase 3 trials are under way and none has reported; zenagamtide is not approved anywhere.

A hand in a blue sleeve holds a white mug at a sunny table with berries, an apple and a glass of water

Is zenagamtide the same drug as amycretin?

Yes. Zenagamtide is the international nonproprietary name (INN), the official generic name the World Health Organization gives a medicine, for the molecule Novo Nordisk developed as amycretin. The WHO proposed it in List 133 in 2025 and recommended it in List 95 in 202667. Novo's own reports switched to "zenagamtide (previously amycretin)" in February 202610, and the 2026 papers use the new name34.

Three names point to the same drug, and you will meet all three:

  • Zenagamtide: the WHO name, used in Novo's reports, the 2026 papers and the newest trial records.
  • Amycretin: the development name, used in the 2025 papers and most news before 2026.
  • NNC0487-0111: Novo's code, used in most ClinicalTrials.gov records, including AMAZE 115.

It matters in the registry: "amycretin" finds one trial, "zenagamtide" 13 and the code 231415. The tables below combine all three.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault charts your weigh-ins over time and logs each weekly shot beside them, so the curve you bring to your clinician is your own, not a trial average.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How does zenagamtide work?

It is two hormone signals built into one chain. The WHO's description reads like a parts list: a modified piece of human GLP-1, a short linker, then an artificial 33-amino-acid piece that switches on the amylin receptor, with a fatty side chain attached6. GLP-1 is the gut hormone behind semaglutide and tirzepatide: it curbs appetite and slows the stomach. Amylin is the fullness hormone the pancreas releases with insulin after a meal. The molecule also switches on the calcitonin receptor, a close relative of the amylin receptor3.

CagriSema sends the same two signals with two drugs in one shot, cagrilintide for amylin and semaglutide for GLP-1. Zenagamtide does it with one molecule, and that one molecule also works as a daily tablet.

The fatty side chain lets the drug ride on albumin, the main protein in blood, so it clears slowly: with normal kidney function, its half-life after one shot was 88.1 hours, about 3.7 days, which suits a weekly shot5.

Try it

How Amycretin builds up

An estimate from a half-life of about 3.7 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleAmycretin in the library

In obese rats, 21 days of the drug cut food intake by 47% and body weight by 18% compared with untreated rats, and in mice it reached the brain areas that control eating16. These are animal results; the human trials follow.

How much weight did people lose on zenagamtide shots?

The first weekly-shot trial took 125 adults with overweight or obesity at one clinic in San Antonio and stepped each group from 0.3 mg up to a different top dose1. The longer and higher the dose, the more weight came off, and the placebo groups barely moved1:

Top weekly dose (trial)WeeksZenagamtidePlacebo
1.25 mg20−9.7%+2.0%
5 mg28−16.2%+2.3%
20 mg36−22.0%+1.9%
60 mg36−24.3%−1.1%

Two limits keep these numbers in proportion. The groups were small, and many people left the study early, a large share of them for reasons unrelated to side effects1. The 36-week figures are also early: the phase 3 weight trials measure their main result at 76 to 84 weeks1113.

PepVault charts your weigh-ins over time and logs each weekly shot beside them, so the curve you bring to your clinician is your own, not a trial average. Track your weight in PepVault

What did zenagamtide do in type 2 diabetes?

A 36-week phase 2 trial at 83 sites in 11 countries gave 262 adults on metformin (some also on an SGLT2 inhibitor) one of six weekly doses or placebo3. The main measure was HbA1c, a three-month average of blood sugar, which started at 7.8%3. Every dose lowered it more than placebo3. The weight numbers come from Novo's release at the ADA meeting in June 2026, counting people while they stayed on treatment9:

Weekly dose (trial)Weight changeHbA1c change (points)
0.4 mg−4.35%−0.91
1.5 mg−7.62%−1.31
5 mg−8.19%−1.00
10 mg−12.92%−1.41
20 mg−13.13%−1.64
40 mg−14.60%−1.71
Placebo−2.10%−0.14

Up to 89.1% of people reached an HbA1c under 7%8. The most interesting line in Novo's first release: people on the highest dose had been on it for only 4 weeks when the trial ended, and at the higher doses weight had not levelled off by week 368. Novo's November 2025 headline said up to 14.5%; its June release gives 14.5% as a dose-response model's estimate and 14.6% as the 40 mg group's result89.

Is there a zenagamtide pill?

Yes, the same molecule as a daily tablet, and it reached phase 3 in September 202613. The first human study of the drug was the tablet: 144 adults, single doses up to 25 mg, then a 12-week step-up to as much as 100 mg a day (two 50 mg tablets)2.

In the type 2 diabetes trial, 186 adults took 6, 25 or 50 mg a day for 36 weeks. HbA1c fell by 0.9, 1.3 and 1.4 points from about 8.0%, all more than placebo4, and weight fell by up to 10.1%, against 2.5% on placebo8. AMAZE 9 now tests five daily doses, from 6 mg to 100 mg, in about 950 people without diabetes for 76 weeks13. These are trial doses, and tablet milligrams do not translate to shot milligrams.

What side effects showed up in the zenagamtide trials?

The familiar GLP-1 pattern: stomach and gut effects lead, mostly mild to moderate. In the obesity shot trial they had mostly cleared by the study's end1. In the first tablet study, every event was mild or moderate, and gut effects made up 49% of them2.

In the diabetes tablet trial, gut effects rose with the dose: 26% of people on 6 mg, 41% on 25 mg and 47% on 50 mg, against 23% on placebo4. In the diabetes shot trial, 8% of people had a serious event, spread across every dose and placebo, and no one died3. Kidney function made little difference to blood levels: the authors judged that no dose change was needed for kidney impairment5.

Commonly reported: stomach and gut effects in every trial so far, most of them mild to moderate1234.

Which zenagamtide trials are running?

ClinicalTrials.gov lists 36 trials under the three names, every one sponsored by Novo Nordisk A/S (as of November 20, 2026)1415. Nineteen are phase 3: the AMAZE trials for weight, the AMBITION trials for type 2 diabetes, and two large heart trials. All are weekly shots except AMAZE 9, the tablet. Completion dates are the registry's estimates for the main result, not results dates.

Phase 3 trialNCTWhat it testsPeoplePrimary completion (est.)Status
AMAZE 1NCT07339423Obesity, vs placebo, 84 weeks1,150Jun 2029Recruiting
AMAZE 2NCT07533175Obesity with type 2 diabetes, vs placebo638Aug 2028Active, not recruiting
AMAZE 3NCT07571005Sleep apnea, no CPAP300Jul 2028Recruiting
AMAZE 4NCT07571109Sleep apnea on CPAP300Jun 2028Recruiting
AMAZE 5NCT07481630Knee osteoarthritis400Aug 2028Recruiting
AMAZE 6NCT07509307Knee osteoarthritis400Aug 2028Recruiting
AMAZE 7NCT07668414Obesity, vs semaglutide650Oct 2028Recruiting
AMAZE 8NCT07400107Obesity with type 2 diabetes, vs semaglutide985Dec 2028Active, not recruiting
AMAZE 9NCT07720271Daily tablet, vs placebo, 76 weeks950Jun 2028Recruiting
AMAZE 10NCT07822061Japan, vs placebo400Feb 2029Recruiting
AMAZE 12NCT07503210Keeping weight off, weeks 40 to 92606Jun 2028Active, not recruiting
AMAZE 13NCT07668401Asia, vs placebo400Jan 2029Not yet recruiting
AMBITION 1NCT07931495Type 2 diabetes on diet and exercise200Jun 2028Not yet recruiting
AMBITION 2NCT07931547Type 2 diabetes with kidney disease, on basal insulin450Jul 2028Not yet recruiting
AMBITION 3NCT07931573Higher doses vs semaglutide1,200Jul 2028Not yet recruiting
AMBITION 4NCT07931599Lower doses vs semaglutide1,060Jul 2028Not yet recruiting
AMBITION 7NCT07797335High heart risk, vs insulin glargine1,778Jul 2028Recruiting
HF-POLARISNCT07567001Heart failure with obesity5,610Jul 2029Recruiting
AMBIENCENCT07861100Heart attack and stroke in heart disease8,500Sep 2030Not yet recruiting

The other 17 are phase 1 and 2 studies of how the body handles the drug and practical questions, among them switching from semaglutide or tirzepatide1415.

NCTPhaseWhat it testsPeopleStatus (primary completion)
NCT053693901First in humans, tablet144Completed Jan 2024
NCT060493291Tablet, Japanese men36Completed Dec 2023
NCT060640062 (1b/2a)Weekly shot, obesity125Completed Nov 2024
NCT064610391Birth control pill, stomach emptying43Completed Mar 2025
NCT064785631Tablet versions and food133Completed Jun 2025
NCT065428742Type 2 diabetes, shot and tablet448Completed Oct 2025
NCT065595271Reduced kidney function42Completed Feb 2025
NCT068204761Tablet, Chinese adults29Completed May 2025
NCT071211531Shot, Chinese adults36Completed Dec 2025
NCT075080201Food intake and appetite120Recruiting, Jan 2028
NCT075353071Insulin release in type 2 diabetes80Recruiting, Nov 2027
NCT075877101Reduced liver function35Recruiting, Dec 2027
NCT077570871Energy use after weight loss120Recruiting, Sep 2028
NCT078150671Tablet: meal timing and water320Recruiting, Jun 2028
NCT078551331Switching from semaglutide60Recruiting, Sep 2028
NCT078683541Switching from tirzepatide60Recruiting, Sep 2028
NCT079441181Fasting, paused doses and the stomach36Not yet recruiting, Jan 2028

When will zenagamtide phase 3 results come out?

Not before 2028, on Novo's timetable. As of November 20, 2026, no phase 3 trial has reported, and this page is updated when one does. The dates Novo has given, each its expectation rather than a fixed date1213:

  • AMAZE 9 (tablet): results in the second half of 2028.
  • AMAZE 7 (vs semaglutide): completion in the second half of 2028.
  • AMBITION 7 (vs insulin glargine): completion in the second half of 2028.
  • AMAZE 8 (vs semaglutide, with diabetes): results in the first half of 2029.
  • AMAZE 10 (Japan): completion in the first half of 2029.
  • HF-POLARIS (heart failure): results in the second half of 2029.
  • AMBIENCE (heart attack and stroke): completion in the second half of 2030.

Novo's reports give no filing date. The registry's earliest primary completion dates fall in June 2028 (AMBITION 1, AMAZE 4, AMAZE 12 and AMAZE 9)1415, so a filing before late 2028 would be a surprise.

If you start a prescribed GLP-1 while these trials run, PepVault can remind you on your shot day and keep each dose and weigh-in in one log. Set reminders in PepVault

Track it in the app

Sources

  1. Dahl K et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406:149-162. PubMed 40550231
  2. Gasiorek A et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. Lancet. 2025;406:135-148. PubMed 40550229
  3. Mora P et al. Efficacy and safety of once-weekly subcutaneous zenagamtide in type 2 diabetes: a dose-finding, phase 2 trial. Lancet. 2026;408:621-635. PubMed 42532080
  4. Mora P et al. Efficacy and safety of once-daily oral zenagamtide in adults with type 2 diabetes: a dose-finding, phase 2 trial. Lancet. 2026;408:607-620. Erratum: Lancet. 2026;408:1704. PubMed 42532079
  5. Oldenburg LIK et al. Renal impairment does not affect pharmacokinetics, safety or tolerability of zenagamtide. Diabetes Obes Metab. 2026;28:8946-8954. PubMed 42443140
  6. World Health Organization. Proposed INN: List 133 (zenagamtide). WHO Drug Information. 2025;39(2). cdn.who.int
  7. World Health Organization. Recommended INN: List 95 (zenagamtide). WHO Drug Information. 2026;40(1). cdn.who.int
  8. Novo Nordisk A/S, Form 6-K: Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. November 25, 2025. sec.gov
  9. Novo Nordisk. Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes, presented at ADA 2026 (PR Newswire release). June 5, 2026. biospace.com
  10. Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026). February 3, 2026. sec.gov
  11. Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2026 to 31 March 2026 (company announcement No 30/2026). May 6, 2026. sec.gov
  12. Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2026 to 30 June 2026 (company announcement No 48/2026). August 4, 2026. sec.gov
  13. Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2026 to 30 September 2026 (company announcement No 65/2026). November 4, 2026. sec.gov
  14. ClinicalTrials.gov. Studies listing zenagamtide (13 records; searched November 20, 2026). clinicaltrials.gov
  15. ClinicalTrials.gov. Studies listing NNC0487-0111 (23 records; searched November 20, 2026). clinicaltrials.gov
  16. Kuhre RE et al. The effect of amycretin, a unimolecular GLP-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025;118:105862. PubMed 40706446

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo